Sustainability | November 01, 2024
Lupin to develop inhalers with near-zero global warming potential propellants
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This product will be manufactured at Lupin's Pithampur facility in India
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
New inhalers would have near-zero Global Warming Potential propellant
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
The company does not expect this development to have any material impact on the current business operations
Subscribe To Our Newsletter & Stay Updated
